English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Interferon alfa-2 is a well-known antiviral therapy with potent antiproliferative properties. Presumably, this has been the basis for its intralesional and short-term topical administration for squamous papillomas. Like other modalities used to treat these lesions, recurrence has been common with interferon therapy. However, recent evidence suggests that long-term administration of interferon alfa-2 is capable of inhibiting angiogenesis. Clinically, it has been used in this manner, for an 8-month duration, to successfully treat various vascular tumors such as hemanigomas, Kaposi sarcoma, and hemangiopericytomas as well as ocular surface neoplasia. We report the use of long-term topical therapy (8 months) with interferon alfa-2 in the successful treatment of recurrent squamous papilloma.

Long-term Administration of Topical Interferon Alfa-2β in the Treatment of Conjunctival Squamous Papilloma